Metabolism of (4-phenoxyphenylsulfonyl)methylthiirane, a selective gelatinase inhibitor

Chemical Biology and Drug Design

Volumn 71, Issue 3, 2008, Pages 187-196

  Celenza, Giuseppe ^a   Villegas Estrada, Adriel ^a   Lee, Mijoon ^a   Boggess, Bill ^a   Forbes, Christopher ^a   Wolter, William R ^a   Suckow, Mark A ^a   Mobashery, Shahriar ^a   Chang, Mayland ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Gelatinase inhibitor; Glutathione adduct; Metabolism

Indexed keywords

(4 PHENOXYPHENYLSULFONYL)METHYLTHIIRANE; CARBENE; CYSTEINE CONJUGATE; GELATINASE INHIBITOR; GLUTATHIONE; SULFINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

ANIMALS; ENZYME INHIBITORS; FEMALE; GELATINASES; GLUTATHIONE; HETEROCYCLIC COMPOUNDS, 1-RING; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFONES; TANDEM MASS SPECTROMETRY;

ANIMALIA; MUS;

EID: 38849184744     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00632.x     Document Type: Article

References (16)

1. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., Mobashery S. (2000) Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 122 : 6799 6800.
2. Bonfil R.D., Sabbota A., Nabha S., Bernardo M.M., Dong Z., Meng H., Yamamoto H., Chinni S.R., Lim I.T., Chang M., Filetti L.C., Mobashery S., Cher M.L., Fridman R. (2006) Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 118 : 2721 2726.
3. Kruger A., Arlt M.J.E., Gerg M., Kopitz C., Bernardo M.M., Chang M., Mobashery S., Fridman R. (2005) Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65 : 3523 3526.
4. Gu Z.Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., Lipton S.A. (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25 : 6401 6408.
5. Lee M., Villegas-Estrada A., Celenza G., Boggess B., Toth M., Kreitinger G., Forbes C., Fridman R., Mobashery S., Chang M. (2007) Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 70 : 371 382.
6. Lee M., Bernardo M.M., Meroueh S.O., Brown S., Fridman R., Mobashery S. (2005) Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett 7 : 4463 4465.
7. Lim I.T., Brown S., Mobashery S. (2004) A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. J Org Chem 69 : 3572 3573.
8. Parkinson A. (2001) Biotransformation of xenobiotics. In : Klaussen C.D., Thomas M.J., Hazucha M.J., editors. Casarett and Doull's Toxicology: The basic science of poisons. New York : McGraw-Hill Medical Publishing Division p. 113 186.
9. Rinaldi R., Eliasson E., Swedmark S., Morgenstern R. (2002) Reactive intermediates and the dynamics of glutathione transferases. Drug Metab Dispos 30 : 1053 1058.
10. Hinson J.A., Pumford N.R., Roberts D.W. (1995) Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab Rev 27 : 73 92.
11. Satoh H., Fukuda Y., Anderson D.K., Ferrans V.J., Gillette J.R., Pohl L.R. (1985) Immunological studies on the mechanism of halothane-induced hepatoxicity: immunohistochemical evidence of trifluoracetylated hepatocytes. J Pharmacol Exp Ther 233 : 857 862.
12. Timbrell J.A., Mitchell J.R., Snodgrass W.R., Nelson S.D. (1980) Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 213 : 364 369.
13. Mitchell J.R., Nelson S.D., Snodgrass W.R., Timbrell J. (1977) Metabolic activation of hydrazines to highly reactive hepatotoxic intermediates. In : Jollow D., Kocsis J., Snyder R., editors. Biological reactive intermediates. New York : Plenum Press p. 271 277.
14. Gardner I., Leeder J.S., Chin T., Zahid N., Uetrecht J.P. (1998) A comparison of covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol 53 : 998 1008.
15. Williams D.P., Pirmohamed M., Naisbitt D.J., Maggs J.L., Park B.K. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283 : 1375 1382.
16. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17 : 3 16.